Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-23

Clinical Trial Update: A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating the efficacy and safety of Tanfanercept (HL036) ophthalmic solution for dry eye disease; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tanfanercept (HL036) ophthalmic solution (Tanfanercept)

Snippet

Sponsor: HanAll BioPharma Co., Ltd. | Conditions: Dry Eye | Phase 3 | Status: COMPLETED | Results posted: 2023-10-23